Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2016

View Archived Issues

CMG-101: an mTORC1/2 inhibitor for RCC

Eli Lilly describes S6K1 inhibitors

Ono and Santen enter enter licensing agreement for ONO-9054

FDA grants orphan drug designation to Adaptimmune's T-cell therapy targeting NY-ESO

Coagadex receives approval in Europe

FDA grants fast track designation for CA4P

EMA's COMP backs orphan drug designation for CDNF in ALS

Inovio announces promising results of human trial evaluating Ebola vaccine

FDA grants fast track designation for VL-2397 as treatment for invasive aspergillosis

Kyorin and Kissei sign codevelopment and co-marketing agreement for KRP-114V in Japan

Shionogi patents HIV protease inhibitors

Shionogi submits NDAs in Japan and the U.S. for naldemedine

Janssen Pharmaceutica discloses orexin receptor antagonists

Neuropore Therapies develops Abeta aggregation inhibitors

Celgene Avilomics Research divulges MK2 inhibitors

Esanex reports HSP90 inhibitors

New phase I/II trial investigates AG-221 or AG-120 with Vidaza for newly diagnosed AML

Actinium's Iomab-B receives FDA orphan drug designation

Gilead Sciences applies for approval of tenofovir alafenamide fumarate in Japan

Radius Health submits NDA for abaloparatide for postmenopausal osteoporosis

Astellas and Mitsubishi Tanabe to share compound libraries

FDA approves use of Roche Zika assay to screen blood donations under IND protocol

aTyr releases phase Ib/II findings for Resolaris in facioscapulohumeral muscular dystrophy

Lexicon submits NDA for telotristat etiprate to treat carcinoid syndrome

Establishment of EA Pharma

FDA approves Defitelio to treat hepatic veno-occlusive disease following HSCT

PLCB4 overexpression shows promise as a prognostic biomarker in GISTs

Researchers investigate TrKA inhibitors for the treatment of chronic pain